Search research articles
Contact Us
Filters
Showing results (391-400 of 738) with videos related to
Page
of 74
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Rare Diseases (Austin, Tex.)
|
March 5, 2016
Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Pilar Ramos, Anthony N Karnezis, William P D Hendricks, et al.
The Lancet. Oncology
|
March 6, 2023
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
Bradley J Monk, Krishnansu S Tewari, Coraline Dubot, et al.
The New England Journal of Medicine
|
September 17, 2021
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 23, 2025
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution
Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology
|
July 19, 2022
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
Dana M Chase, Margarita Romeo Marín, Floor Backes, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Page
of 74
Search research articles
Search
Showing results (391-400 of 738) with videos related to
Sort By:
Page
of 74
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Rare Diseases (Austin, Tex.)
|
March 5, 2016
Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Pilar Ramos, Anthony N Karnezis, William P D Hendricks, et al.
The Lancet. Oncology
|
March 6, 2023
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
Bradley J Monk, Krishnansu S Tewari, Coraline Dubot, et al.
The New England Journal of Medicine
|
September 17, 2021
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 23, 2025
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution
Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
Gynecologic Oncology
|
July 19, 2022
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
Dana M Chase, Margarita Romeo Marín, Floor Backes, et al.
Journal of Gynecologic Oncology
|
July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
Page
of 74